Guggenheim initiated coverage on Tempus AI with a new price target
$TEM
Computer Software: Programming Data Processing
Technology
Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $85.00 | Overweight | Morgan Stanley |
| 10/21/2025 | $88.00 | Buy → Hold | TD Cowen |
| 10/20/2025 | $110.00 | Buy | Canaccord Genuity |
| 9/2/2025 | $90.00 | Buy | H.C. Wainwright |
| 4/21/2025 | $60.00 | Buy | BTIG Research |
| 2/25/2025 | $50.00 → $55.00 | Overweight → Neutral | Analyst |
| 2/12/2025 | Outperform → Mkt Perform | William Blair | |
| 2/5/2025 | $58.00 → $74.00 | Buy | TD Cowen |
Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health's Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center, a comprehensive, pan-cancer initiative to more deeply understand disease biology over time. The research seeks to enhance genomic diagnostics to improve patient outcomes, inform future clinical practice, and accelerate the development and validation of novel assays and
Collaboration will focus on the oncology patient population Northwestern Medicine and Tempus AI, Inc. (NASDAQ:TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding of their unique cancer, enabling clinicians to deploy tailored, effective treatments. "The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage ca
Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% 2025 Net revenue retention of ~126% Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs incl
8-K - Tempus AI, Inc. (0001717115) (Filer)
144 - Tempus AI, Inc. (0001717115) (Subject)
144 - Tempus AI, Inc. (0001717115) (Subject)
4 - Tempus AI, Inc. (0001717115) (Reporting)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A
Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00
TD Cowen downgraded Tempus AI from Buy to Hold and set a new price target of $88.00
Canaccord Genuity initiated coverage of Tempus AI with a rating of Buy and set a new price target of $110.00